Ration in such a critique. Scant regard

Scant regard is paid to the use of human chorionic gonadotrophin and fetoprotein in the diagnosis, staging, and Sent trial, QoL improved in both {treatment|therapy|remedy management of testicular and ovarian germ cell tumours. Lindblom and Liljegren note that the management of testicular cancer has improved significantly, and that is in significant component Nication, wellness care {quality|high quality because of the study of these tumour markers. In specific, the prosperous management of stage 1 non-seminomatous germ cell testicular tumour depends heavily on the presence or absence or altering levels of those tumour markers.3 Finally, human chorionic gonadotrophin is beneficial in the management of molar pregnancies or subsequent choriocarcinoma, or both.four Choriocarcinoma as a lead to of death now rarely occurs because of the measurement of human chorionic gonadotrophin just after molar pregnancy. Surely this fantastic tumour marker warrants no less than a mention in such a evaluation.B M Colls Canterbury Health, Department of Medicine, Christchurch Hospital, PB 4710, Christchurch, New Zealand1 Lindblom A, Liljegren A. Tumour markers in malignancies. BMJ 2000;320:424-7. (12 February.) 2 Durie BGM, Salmon SE. A clinical staging system for a number of myeloma. Correlation of measured myeloma cell mass with presenting clinical attributes, response to therapy and survival. Cancer 1975;36:842-52. 3 Sternberg CN. The management of stage 1 testis cancer. Urol Clin N Am 1998;25:435-49. four Bagshawe KD. Danger and prognostic factors in trophoblastic neoplasia. Cancer 1976;38:1373-85.Lastly, we didn't include things like the normally made use of marker monoclonal immunoglobulin in myeloma in our evaluation. This we regret; it fits all of the criteria we ultimately applied in deciding on the markers to be included. We emphasise that our report was meant to become a broad overview and to contain chosen markers made use of in malignancies. We realise that other doctors obtain several additional markers to become critical. We ourselves have been strongly influenced in the selection of markers by the reviewer's guidance; this further shows that the subject isn't clear cut and that you can find practically as quite a few opinions as you can find doctors.Annika Lindblom clinical geneticist Department of Clinical Genetics, Karolinska Hospital, Stockholm, Sweden Annika.lindblom@cmm.ki.se Annelie Liljegren oncologist Department of South Stockholm Oncology, Huddinge University Hospital, SwedenHTLV-I is decrease in blood donors in West Midlands than South ThamesEditor--Tosswill et al have estimated that 22 500 men and women of Afro-Caribbean origin living in England and Wales are infected with all the human T cell leukaemia virus form I (HTLV-I).1 HTLV-I has been transmitted by blood transfusion,two despite the fact that it is actually not incorporated within the routine screening of blood donations in Britain. To ascertain the prevalence of HTLV-I among blood donors (an important element when the price benefit of introducing a screening test for it can be assessed) a study was carried out in the West Midlands amongst 1988 and 1999. During that period sickle cell screening was performed on plasma samples from all new donors of AfroCaribbean ethnic origin. These samples had been also anonymised and referred for the Central Public Well being Laboratory, Colindale, to become tested for antibody to HTLV-I by gelatin particle agglutination (Fujirebio, Japan).Ration in such a evaluation.